Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients

In patients with chronic heart failure (CHF)due to dilated cardiomyopathy diastolic dysfunction occurs frequently and is related to a poor outcome. We have previously shown that parameters of diastolic function significantly correlate with uric acid levels, a marker of impaired oxidative metabolism. We aimed to determine whether inhibition of xanthine oxidase with allopurinol might affect diastolic function in patients with CHF.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Heart Failure

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Division of Cardiology, University Hospital of Verona

Verona, 37129, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

chronic heart failure;
left ventricular systolic dysfunction (ejection fraction <45%)
stable clinical conditions in the previous three months
optimal medical therapy for CHF
normal sinus rhythm
written informed consent
age >18 years

Exclusion criteria

renal failure (s-creatinine >2.5 mg/dl)
already on allopurinol
malignancies
chronic inflammatory diseases

Treatment and study plan

Allopurinol

Drug

Primary outcomes

diastolic function uric acid levels BNP

Time frame: three months

Sponsors and collaborators

Lead sponsor

Universita di Verona

Other

Registry information

Important dates

First posted: May 24, 2007
Registry last updated: May 24, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed